Form 4: C4 Therapeutics CFO Reports Stock Transactions

C4 Therapeutics' Chief Financial Officer, Kendra Adams, reported the acquisition of common stock through RSU vesting and subsequent disposition for tax obligations.

Summary

• Kendra Adams, Chief Financial Officer of C4 Therapeutics, Inc. (CCCC), reported changes in her beneficial ownership of common stock.
• On September 18, 2025, Ms. Adams acquired 6,250 shares of common stock upon the vesting of previously granted restricted stock units (RSUs).
• Following this acquisition, her direct beneficial ownership increased to 165,117 shares.
• Concurrently, on September 18, 2025, 2,775 shares of common stock were disposed of at a price of $3.32 per share to satisfy tax withholding obligations related to the RSU vesting.
• After both transactions, Ms. Adams' direct beneficial ownership stands at 162,342 shares of common stock.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to executive compensation (RSU vesting and tax withholding). These events are neutral in nature and do not indicate positive or negative sentiment regarding the company's operational or financial performance.

Positives

• The vesting of 6,250 restricted stock units indicates compensation for the Chief Financial Officer, aligning management's interests with shareholder value.
• The acquisition of shares through RSU vesting increases the CFO's direct stake in the company, demonstrating continued commitment.

Negatives

• The disposition of 2,775 shares to cover tax withholding obligations resulted in a reduction of the CFO's overall direct beneficial ownership by that amount.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing details a routine insider transaction related to executive compensation, specifically the vesting of restricted stock units and subsequent tax withholding. Such transactions are common across all industries for publicly traded companies and do not typically reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The transactions represent a routine change in an executive's direct ownership, which is a standard part of executive compensation and generally has minimal direct impact on other shareholders.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Keywords

C4 Therapeutics, CCCC, Kendra Adams, Chief Financial Officer, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Stock Ownership, Tax Withholding